The mechanisms involved in maintaining a latent replication-competent integrated human immunodeficiency virus type 1 (HIV-1) reservoir after successful highly active antiretroviral therapy (HAART) have not been fully described. The objective of this study was to assess whether low-level, persistent HIV-1 replication can be detected in the protease gene, in 10 HIV-1-infected patients who have undergone 2 years of successful HAART. Peripheral blood mononuclear cells (PBMCs) were collected from 10 HIV-1-infected patients receiving a triple-drug combination therapy (2 nucleoside analogues and 1 protease inhibitor). HIV-1 RNA levels and CD4 + and CD8 + T cell counts were longitudinally determined during a follow-up period of 108 weeks. Similarly, proviral fragments of the protease-coding region, obtained at baseline and at week 108 of HAART, were amplified by polymerase chain reaction from PBMCs, and 10-25 individual clones were sequenced for each time point. Only 1 of 271 individual protease clones showed a major resistance substitution (M46I [patient D]). Phylogenetic analysis revealed that, in all patients, the genetic distances from the deduced most recent common ancestor, in samples obtained at week 108 of HAART, were not longer than those in samples obtained at baseline. Moreover, the pattern of amino acid divergence during therapy showed an absence of positive selection in the protease-coding region. Taken together, these results show a lack of clinically relevant evolution in the protease-coding region after 2 years of successful HAART.
the preservation of the latent HIV-1 reservoir after successful HAART. First, the stability of this latent HIV-1 reservoir has been associated with the long life span of latently infected cells [6] [7] [8] . Second, low levels of ongoing viral replication have also been correlated with the slow decay of the latent HIV-1 reservoir [9] [10] [11] [12] [13] [14] . Understanding the nature of persistence of HIV-1 after HAART has important implications in the clinical management of HIV-1 infection, because low levels of viremia can be interpreted as viral replication in the presence of drugs, and the subsequent emergence of drug-resistant mutants. Since eradication with the current therapies is unlikely, emergence of drug-resistant substitutions and long-term drug toxicity seem to be the main drawbacks of current HAART.
We have previously studied the latent HIV-1 reservoir present in peripheral blood mononuclear cells (PBMCs) from 10 HIV-1-infected patients receiving HAART [15] . In addition, we have also investigated the HIV-1-integrated proviral sequence variation in PBMCs from 4 of these patients [16] . The former studies demonstrated that 2 years of successful HAART did not significantly reduce either the size or the genetic repertoire of the integrated provirus population, emphasizing the stability of the latent HIV-1 reservoir after successful HAART. Here, we present the HIV-1 protease proviral sequence variation in PBMCs from these 10 patients. Proviral fragments of the protease-coding region from samples obtained at baseline and at week 108 of HAART were amplified by polymerase chain reaction (PCR) from PBMCs, and 10-25 individual clones were sequenced for each time point. Analysis of phylogenetic and genetic distance revealed an intermingling of sequences from the 2 time points; that is, distinct, temporal clustering of sequences at each time point was not observed. This pattern is indicative of an absence of genetic change in this locus during the time period analyzed.
PATIENTS, MATERIALS, AND METHODS

Patients.
Ten drug-naive HIV-1-infected patients who started HAART were selected for the present study [15] . The clinical characteristics of the patients are shown in table 1. Longitudinal evolution of blood CD4 + T cell counts and HIV-1 RNA levels are shown in figure 1A . Plasma HIV-1 RNA levels were measured by use of the Amplicor monitor assay (Roche).
Recovery and analysis of DNA and RNA sequences. Purification of genomic PBMC DNA was performed as described elsewhere [15] . Endpoint dilution of PBMC DNA was performed before nested PCR was performed, to make products derived from a single provirus [10, 16] . For each sample, at least 10 amplicons were directly sequenced by use of a 310 automated sequencer and dRhodamine chain terminator chemistry (Applied Biosystems). The protease gene was amplified by use of the following published [17] oligonucleotides: 5 prot 1 and 3 prot 1, for the first PCR, and 5 prot 2 and 3 prot 2, for the nested PCR. PCR conditions have also been published elsewhere [17] . The plasma sample obtained from patient D at week 72 of HAART was processed for RNA extraction, as described elsewhere [16] . The viral RNA was retrotranscribed into cDNA with 3 prot 1. cDNA was amplified by use of PCR with 5 prot 1 and 3 prot 1, followed by a second round of amplification, with 5 prot 2 and 3 prot 2. For the PBMC samples, endpoint dilution of the cDNA was performed before nested PCR was performed. The sequencing oligonucleotides used were 5 prot 2 and 3 prot 2. Sequences were aligned by use of ClustalW (http://www.ebi.ac.uk/clustalw/) [18] . Pairwise nucleotide distances were calculated by use of the F84 model of evolution with a transition:transversion ratio of 2:1, as implemented in the PHYLIP software package (version 3.6; http:// evolution.genetics.washington.edu/phylip.html) [19] . Phylogenetic reconstructions were generated by use of the neighborjoining method included in the PHYLIP software package [19] . Bootstrap resampling [19] was applied to the neighbor-joining trees, to assign approximate confidence limits to individual branches. The final graphic output was created with the TREEVIEW program (http://taxonomy.zoology.gla.ac.uk/rod/ treeview.html) [20] . The proportion of synonymous substitutions per potential synonymous sites (ds) and the proportion of nonsynonymous substitutions per potential nonsynonymous sites (dn) were calculated with the MEGA program (version 2.1; http://www.megasoftware.net), by use of the modified NeiGojobori model of evolution [21] . Using the neighbor-joining tree, we calculated the most recent common ancestor (MRCA) for every complete intrapatient sequence group. We then calculated the distances to the MRCA for each individual sequence. Two groups of sequences were considered: those from the MRCA to the sequence from the sample obtained at baseline and those from the MRCA to the sequence from the sample obtained at week 108 (table 2) . Distances between the MRCA and sequences from the sample obtained at baseline and the MRCA and the sequences from the sample obtained at week 108 were subjected to nonparametric statistical treatment by use of the Wilcoxon signed rank test, which is included in the SPSS software package (version 7.5; SPSS). Seventeen GrA hypermutated sequences [22, 23] , isolated from 5 different patients (GenBank accession numbers AY255454-AY255470; figure 2), were not included in the tree or in subsequent sequence analysis.
Nucleotide sequence accession numbers. The nucleotide sequence data reported in this article have been submitted to the GenBank database (accession numbers AY255183-AY255470).
RESULTS
The clinical characteristics of the analyzed patients during the study period are summarized in figure 1 and table 1. In brief, plasma HIV-1 RNA remained undetectable in 6 patients during the study period. Patient D stopped therapy after week 70 of HAART, and a rebound of plasma virus level was detected at week 72. Patient D resumed therapy (lamivudine, stavudine, nevirapine, and nelfinavir) at week 93 and again showed an undetectable plasma virus level at week 108 ( figure 1A ). Intermittent episodes of low-level viremia ("blips") were observed in patients E, F, and J. A gradual, significant increase in CD4 + T cell counts was observed at week 108 of HAART (mean at baseline, cells/mL; mean at week 108, 626 ‫ע‬ 249 1101 ‫ע‬ 283 cells/mL;
, Wilcoxon signed rank test). These results P ! .005 show that long-term suppression of virus and success of treatment were achieved in our cohort of patients.
Absence of protease evolution after 2 years of successful HAART. To evaluate the genetic evolution of the protease- coding region after 2 years of successful HAART, we analyzed the HIV-1 protease proviral sequence variation in PBMCs from the 10 study patients. Proviral fragments of the protease-coding region obtained at baseline and at week 108 of HAART were amplified by PCR from PBMCs, and 10-25 individual clones were sequenced for each time point. Endpoint dilution of PBMC DNA was performed before PCR was performed, to make products derived from a single provirus. Although 271 individual clones were sequenced, only 1 showed a major resistance substitution (M46I [patient D]) (figure 2). As mentioned above, patient D stopped therapy at week 70 and resumed therapy at week 93. This result demonstrates that 2 years of suppression of plasma virus level as a result of therapy regimens that include protease inhibitors prevents the development of minority protease-resistant variants.
Phylogenetic reconstruction of all protease sequences revealed, for each patient, an intermingling of sequences from the 2 time points analyzed; that is, distinct temporal clustering of sequences at each time point was not observed (figure 2).
This trend was quantitatively evaluated by calculating the genetic distances from the deduced MRCA to sequences obtained at different time points (table 2) . Since mutational changes accumulate as a result of completed rounds of viral replication, for viruses isolated at later time points, active viral replication should translate to longer genetic distance to the MRCA. However, in all the patients analyzed here, the samples obtained at baseline and at week 108 showed similar genetic distances to the MRCA (table 2) , suggesting an absence of viral evolution during the study period. Moreover, the sequences from the plasma sample obtained from patient D at week 72 also showed genetic distances to the MRCA that were similar to those calculated with the baseline sample (table 2 and figure 2) . Similarly, sequences from the samples obtained at week 108 from patients E, F, and J, in whom blips were observed during the study period, did not show longer genetic distances to the MRCA. This result suggests that the former blips did not significantly contribute to the evolution of the protease gene.
Selection pressure on HIV-1 protease sequences was deter- mined by analyzing the synonymous (silent) and nonsynonymous (amino acid-changing) nucleotide substitution patterns. Dominance of the rate of nonsynonymous nucleotide substitutions over the rate of synonymous substitutions indicates evidence of positive selection. We have previously observed a significant decrease in the ds:dn ratios in protease sequences obtained from patients for whom monotherapy with protease inhibitors failed [17] . These lower ds:dn ratios, detected after therapy, demonstrate the strong positive selection exerted by the drug on the protease gene during the period that the patient is receiving HAART. The mean values of nucleotide substitutions per synonymous site and per nonsynonymous site, for all pairwise sequence comparisons at both time points, were then calculated (table 3) . As expected, the high ds:dn ratios (mean ds: dn, ) observed at baseline indicate no selection (neu-8.2 ‫ע‬ 8.3 trality) at this locus. Values obtained with the sequences from the samples obtained at week 108 showed no significant decrease in the ds:dn ratios (mean ds:dn, ), indicating an absence 7.0 ‫ע‬ 3.6 of selection at this locus similar to that found in the sequences from the samples obtained at baseline.
Stability of the protease genetic repertoire after 2 years of suppression of plasma HIV-1 levels. We next calculated the intrasample genetic distances to assess whether 2 years of suppression of plasma virus levels resulted in reduction of the protease genetic repertoire. We have previously showed, for patients B, C, D, and H, that 2 years of successful HAART did not significantly reduce the genetic repertoire of the integrated long terminal repeat (LTR) sequence population [16] ; here, we have extended this analysis to the 10 study patients and to the protease-coding region (table 3) . Similar to what we found in the integrated LTR sequences, 2 years of successful HAART does not reduce the protease genetic repertoire (table 3) , emphasizing again the high stability of the latent HIV-1 reservoir during HAART. Taken together, the results presented here do not provide support for clinically relevant evolution of the protease gene after 2 years of successful HAART.
DISCUSSION
Eradication of HIV-1 cannot be achieved with available antiretroviral therapies, mainly because of the existence of a pool of latently infected CD4 + T cells established early during acute HIV-1 infection, a pool that persists even with prolonged suppression of plasma viremia [6, 7] . For that reason, this reservoir of latently infected cells has been extensively studied, to gain insight into its role in the pathogenesis of HIV-1, as well as its role in the durability and success of current antiretroviral regimens. The stability of this pool of latently infected CD4 + T cells, even after long periods of suppression of plasma virus levels, has been associated with the inability of current drug combinations to completely block HIV-1 replication [9] [10] [11] [12] [13] [14] . In contrast, persistence has also been associated with the long life span of memory CD4 + T lymphocytes [8] . The evolution of latently infected CD4 + T cells after HAART has important implications in the clinical treatment of HIV-1-infected patients, because, if there are new cycles of replication in the presence of drugs when the level of viremia is undetectable (!20 copies/ mL), the development of drug-resistant variants and subsequent treatment failure would be expected. With the advent of more-sensitive assays to quantify the HIV-1 RNA level, it seems evident that, in most patients receiving suppressive antiretroviral therapy (viremia !20 copies/mL), it is possible to detect persistent viremia. Whether this low level of persistent viremia results from basal cellular transcription of HIV-1 RNA in resting CD4 + T cells, as has been recently suggested [8, 24] , or whether it is the consequence of ongoing viral replication remains to be elucidated. The question that we wanted to address here was whether it is possible to detect clinically relevant, ongoing HIV-1 replication after 2 years of successful HAART. For 9 of the 10 patients studied in the present study, clonal genotypic analysis failed to detect minority subpopulations containing protease drug-resistant substitutions. Only patient D had a clone with a major protease-resistance substitution (M46I) (figure 2). In a previous study, replication-competent, protease drug-resistant virus was isolated from patients receiving HAART regimens who did not show a sustained rebound of plasma HIV-1 RNA level to 150 copies/mL [25] . Nevertheless, the former investigators failed to detect antiretroviral-resistant viruses in drugnaive patients who started HAART. Results similar to those shown here have been obtained by amplifying the virus present in the plasma of patients with low levels of viremia (!50 copies/ Figure 2 . Neighbor-joining phylogram of proviral protease sequences from peripheral blood mononuclear cells (PBMCs) from the 10 patients analyzed in the present study. The plasma HIV-1 RNA population in patient D at 72 week is also shown (gray). Phylogenetic reconstruction of all protease sequences showed that clones clustered in a patient-specific manner, indicating the absence of polymerase chain reaction product cross-contamination. Phylogenetic reconstruction was generated by use of a F84 distance matrix fed into a neighbor-joining tree construction algorithm, as implemented in the PHYLIP software package (version 3.6). Nos. at branch nodes refer to the no. of bootstrap repetitions (total, 100) at which the distal sequences grouped together; only those 150% are shown. Nine hypermutated sequences from patient A (GenBank accession nos. AY255454-AY255462), 4 from patient G (GenBank accession nos. AY255465-AY255468 ), 2 from patient I (GenBank accession nos. AY255469-AY255470 ), 1 from patient D (GenBank accession no. AY255463), and 1 from patient F (GenBank accession no. AY255464 ) were not included in the analysis. mL) who had received prolonged HAART [26] . In fact, in untreated patients, the plasma virus was wild type (wt), and, in patients who had received prior nonsuppressive therapy, it was wt and archival drug-resistant viruses. Comparable results have recently been reported for pediatric patients [27] . With respect to the data presented here, it is important to emphasize that patients E, F, and J (figure 1), in whom blips were observed during the study period, did not harbor, at week 108, proviral sequences with longer genetic distances to the MRCA (figure 2). These results indicate an absence of significant continuous cycles of the de novo infection of susceptible cells, even in patients in whom episodes of viremia are evident. This does not mean that there was no replication; it shows only that the rate of replication is too low to allow substantial evolution in the protease gene. Therefore, detection of plasma virus may not represent treatment failure or the evolution of drug resistance. These results are also in agreement with those of studies in which intermittent viremia was not associated with virologic failure in patients receiving HAART [28] . Previous studies of the evolution of HIV-1 in infected adult patients receiving HAART have revealed a variety of patterns, ranging from the accumulation of mutations to a very static pattern suggestive of a halt in viral evolution. Sequence evolution in the C2 to V3 domains of the HIV-1 env gene, suggestive of ongoing viral replication, could be detected in some patients, whereas a halt in viral evolution was observed in others [12, 13, 29] . Similarly, studies of sequence evolution in the pol gene, in infected children, have shown low levels of viral replication during successful HAART [14] . However, a comparable study of pediatric patients has revealed an absence of viral evolution in the pol gene after several years of extensive antiretroviral exposure [27] . In the present study, we have shown that the proviral protease sequences detected after 2 years of successful HAART, in infected adults without previous antiretroviral experience, represent largely wt or archival HIV-1, rather than recently generated drug-resistant mutants (figure 2). Since we have analyzed only viral sequences present in PBMCs, we may be missing viral evolution that is occurring elsewhere (e.g., in peripheral lymphoid organs). However, data on resistance mutations in lymph nodes (LNs), described by several groups, argue against this possibility. Thus, Schapiro et al. [30] demonstrated that the presence or absence of saquinavir-resistant substitutions were identical in 13 of 14 LN biopsy specimens, suggesting that saquinavir-resistance mutations appear in close temporal proximity in LNs and in plasma. Similarly, a high concordance for drug-resistance mutations has been found in proviral DNA from both PBMCs and LN tissue [31, 32] . Overall, the results presented here and in previous reports strongly suggest an absence of minority drug-resistant virus in patients receiving successful HAART. One limitation of our study is that we have not analyzed the appearance of drug resistance in the reverse transcriptase (RT)-coding region, where, it has been suggested, it might be easier to observe viral evolution, because a single mutation can confer resistance to some drugs (e.g., RT M184V) [32] . However, the emergence of resistance to RT inhibitors must be the result of completed rounds of replication, and, therefore, for viruses arising at later time points, active viral replication should translate to longer genetic distances to the MRCA, not only in the RT gene but in every viral gene, including the protease-coding region.
An important aspect of the present study is that the current antiretroviral therapies are ineffective at reducing the latent HIV-1 genetic repertoire. Thus, as we have suggested before [16] , suppressive-treatment protocols that include structured interruption of therapy must take into account that the virus population that will emerge may contain the entire repertoire of variants (e.g., drug-resistant mutants and syncytium-inducing viruses) that were present before the beginning of therapy. This is particularly important in patients who have previously received nonsuppressive antiretroviral therapy, because previ-ously selected drug-resistant viruses may be selected in future regimens.
The absence of clinically relevant, ongoing HIV-1 replication after long periods of receiving HAART has important implications for treatment of patients. Two years of successful HAART, with virus levels below the limit of detection, by conventional methods does not allow, even when a limited degree of viral replication is detected, the development of protease drug-resistant mutations. Therefore, early detection of toxicity and nonadherence may be essential to prevent emergence of drug resistance and treatment failure. Nontoxic drugs or compounds with different toxicity profiles can augment the current therapeutic options as well as increase the period of suppressive antiretroviral therapy.
